Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 6/20 | 0.32 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.32 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31748452 | 0.80 | PRKAB2 (0.35) | PTGER4 | |
| SCHEMBL31748311 | 0.78 | EGFR (0.33) | PLA2G2APLA2G10PLA2G1BPLA2G5ALDH1A1 | |
| SCHEMBL31748586 | 0.76 | DGAT1 (0.35) | NPC1DGAT1 | |
| SCHEMBL31748606 | 0.74 | DGAT1 (0.33) | NPC1DGAT1 | |
| SCHEMBL31748488 | 0.73 | PTGER4 (0.33) | PTGER4PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL31748679 | 0.73 | DGAT1 (0.36) | PLA2G2APLA2G10PLA2G1BPLA2G5DGAT1 | |
| SCHEMBL31748334 | 0.72 | PLA2G2A (0.36) | PTGER4PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL31748438 | 0.71 | EGFR (0.35) | ALDH1A1DGAT1 | |
| SCHEMBL31748756 | 0.71 | PTGER4 (0.34) | PTGER4ALDH1A1DGAT1 | |
| SCHEMBL31748407 | 0.71 | NPC1 (0.34) | NPC1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | PTGER4 3357/4885PLA2G2A 2787/4885PLA2G10 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.